-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the "Notice on Doing a Good Job in the Centralized Procurement and Use of the Fifth Batch of National Organizations of Drugs" recently issued by the Guangdong Medical Insurance Bureau and other three departments, the province will implement the fifth batch of centralized procurement from 0:00 on October 9, 2021.
Winning results and supporting policies
.
In other words, in early October, Guangdong Province will usher in a batch of price-cut drugs
.
So, what are the price-cut drugs selected in the fifth batch of centralized procurement? According to the results of the fifth batch of national procurement, a total of 61 drugs to be purchased were successfully purchased, and 148 companies and 251 products were selected
.
61 kinds of medicines involve not only drugs for common diseases such as hypertension, coronary heart disease, diabetes, gastrointestinal diseases, and chronic diseases, but also drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer.
More than half of them are injections, with an average price reduction of 56%
.
The notice requires that all localities should make advance payment of medical insurance funds in advance, adjust the medical insurance payment system (the medical insurance payment standard will be issued separately), carry out training for handling agencies and medical institutions, strengthen the monitoring of the use of selected drugs and contract performance, and ensure the use and guarantee Quality, guarantee supply, guarantee payment collection, and ensure the implementation of the fifth batch of centralized procurement policies
.
According to the fifth batch of 61 countries’ centralized drug procurement (Guangdong), the selected products include ω-3 fish oil medium/long-chain fat emulsion injection, aripiprazole tablets, and esomeprazole sodium for injection.
, Decitabine for injection, docetaxel injection, dutasteride soft capsules, rivaroxaban tablets, olopatadine hydrochloride tablets, oxaliplatin injection, cefazolin sodium for injection, etc.
, among which injections Become the main dosage form, its quantity accounted for half of the total number of products collected this time, and the amount involved accounted for about 70% of the total amount of this collection
.
Among the 61 selected products, there are many large varieties of more than 1 billion
.
For example, according to data from Meinenet, in 2019, the sales of iodixanol and iohexol in public medical institutions in China both exceeded 3.
5 billion yuan.
In addition, docetaxel injection is also a large variety with a market capacity of more than 3 billion
.
From the perspective of price reductions, in the fifth batch of centralized procurement, the price reductions of drugs are also fierce.
For example, the price of fluconazole of Kelun Pharmaceutical has been reduced by 65%, and the price of omega-3 fish oil medium/long-chain fat emulsion injection has been reduced by more than 80%.
%
.
Qilu Pharmaceutical's rivaroxaban was reduced by 98%, docetaxel was reduced by 94%, and oxaliplatin was reduced by 89%
.
In addition, according to the fifth batch of 61 national drug centralized procurement (Guangdong) selected products, the number of selected companies is different, and the agreed procurement volume is also different
.
For example, two companies are selected for the omega-3 fish oil medium/long-chain fat emulsion injection 100ml, and the agreed purchase amount is calculated at 60% of the calculation base.
Pharmacies agreed to purchase 472.
2; ω-3 fish oil medium/long-chain fat emulsion injection 250ml was selected by 2 companies, and their agreed purchases were calculated at 60% of the calculation base, and their agreed purchases were 876, of which public hospitals agreed to purchases 816, designated privately-owned and pharmacies agreed to purchase 60
.
The purpose of centralized procurement is to "squeeze water" and through group purchase of drugs, so that the general public can continue to see diseases, afford drugs, and use good drugs.
At the same time, it is conducive to forcing the entire pharmaceutical industry to innovate and upgrade.
Entering the track of healthy development
.
With the landing of this batch of reduced-price drugs, it will be great news for the insured patients in Guangdong Province
.
Winning results and supporting policies
.
In other words, in early October, Guangdong Province will usher in a batch of price-cut drugs
.
So, what are the price-cut drugs selected in the fifth batch of centralized procurement? According to the results of the fifth batch of national procurement, a total of 61 drugs to be purchased were successfully purchased, and 148 companies and 251 products were selected
.
61 kinds of medicines involve not only drugs for common diseases such as hypertension, coronary heart disease, diabetes, gastrointestinal diseases, and chronic diseases, but also drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer.
More than half of them are injections, with an average price reduction of 56%
.
The notice requires that all localities should make advance payment of medical insurance funds in advance, adjust the medical insurance payment system (the medical insurance payment standard will be issued separately), carry out training for handling agencies and medical institutions, strengthen the monitoring of the use of selected drugs and contract performance, and ensure the use and guarantee Quality, guarantee supply, guarantee payment collection, and ensure the implementation of the fifth batch of centralized procurement policies
.
According to the fifth batch of 61 countries’ centralized drug procurement (Guangdong), the selected products include ω-3 fish oil medium/long-chain fat emulsion injection, aripiprazole tablets, and esomeprazole sodium for injection.
, Decitabine for injection, docetaxel injection, dutasteride soft capsules, rivaroxaban tablets, olopatadine hydrochloride tablets, oxaliplatin injection, cefazolin sodium for injection, etc.
, among which injections Become the main dosage form, its quantity accounted for half of the total number of products collected this time, and the amount involved accounted for about 70% of the total amount of this collection
.
Among the 61 selected products, there are many large varieties of more than 1 billion
.
For example, according to data from Meinenet, in 2019, the sales of iodixanol and iohexol in public medical institutions in China both exceeded 3.
5 billion yuan.
In addition, docetaxel injection is also a large variety with a market capacity of more than 3 billion
.
From the perspective of price reductions, in the fifth batch of centralized procurement, the price reductions of drugs are also fierce.
For example, the price of fluconazole of Kelun Pharmaceutical has been reduced by 65%, and the price of omega-3 fish oil medium/long-chain fat emulsion injection has been reduced by more than 80%.
%
.
Qilu Pharmaceutical's rivaroxaban was reduced by 98%, docetaxel was reduced by 94%, and oxaliplatin was reduced by 89%
.
In addition, according to the fifth batch of 61 national drug centralized procurement (Guangdong) selected products, the number of selected companies is different, and the agreed procurement volume is also different
.
For example, two companies are selected for the omega-3 fish oil medium/long-chain fat emulsion injection 100ml, and the agreed purchase amount is calculated at 60% of the calculation base.
Pharmacies agreed to purchase 472.
2; ω-3 fish oil medium/long-chain fat emulsion injection 250ml was selected by 2 companies, and their agreed purchases were calculated at 60% of the calculation base, and their agreed purchases were 876, of which public hospitals agreed to purchases 816, designated privately-owned and pharmacies agreed to purchase 60
.
The purpose of centralized procurement is to "squeeze water" and through group purchase of drugs, so that the general public can continue to see diseases, afford drugs, and use good drugs.
At the same time, it is conducive to forcing the entire pharmaceutical industry to innovate and upgrade.
Entering the track of healthy development
.
With the landing of this batch of reduced-price drugs, it will be great news for the insured patients in Guangdong Province
.
